🇺🇸 FDA
Patent

US 10568956

Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes

granted A61KA61K2039/5258A61K2039/53

Quick answer

US patent 10568956 (Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes) held by The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services
Grant date
Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/5258, A61K2039/53, A61K2039/57, A61K2039/575